Reply letter to “Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial”

Abstract

A recent study reported that the high-dose quadrivalent influenza vaccine provided superior immunogenicity and efficacy versus the standard-dose quadrivalent vaccine in the elderly. However, we need to view these results in terms of public health benefits as well. The Number Needed to Vaccinate (NNV) is an important tool to measure the benefit of a given vaccine. Further, NNV evaluates the benefits of a vaccine in preventing and controlling communicable diseases. Considering the target of vaccination and coverage of 75% not met in the elderly in Europe, it is important not to prioritize one vaccine over the other, but rather to increase the vaccine coverage with all the available vaccines.

Reply to letter to editor by Hadigal et al. regarding the immunogenicity and safety trial of high-dose influenza vaccine in adults aged ≥60 years

“… 1 We recently published an immunobridging trial demonstrating superior immunogenicity and similar reactogenicity of high dose quadrivalent influenza vaccine (IIV4-HD) vs. standard dose quadrivalent vaccine (IIV4-SD) in adults aged ≥60 years. 2 Hadigal et al from Viatris Inc. commented on IIV4-HD following our publication, 3 and here we would like to address their viewpoints.…”

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

“… 13 , 14 Characterizing vaccination benefits in terms of NNV across diverse geographic settings and populations can support key policy, guidance, and resource allocation decisions such as booster timing, prioritization, and coverage among focal populations. 15 , 16 Furthermore, these insights can be extended into economic and cost-effectiveness evaluations. 13 , 14 …”